BOTHELL, Wash., Sept. 28 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM) today announced that Lori H. Bush, a 25-year
veteran of the medical and consumer health and beauty industries, has been
named Chief Operating Officer, a new position at the Company. Her focus
will be the commercialization of the Helix BioMedix portfolio of
cosmeceutical and pharmaceutical peptide technologies.
Prior to joining Helix BioMedix, Ms. Bush was President of Nu Skin, the
$500 million personal care products division of Nu Skin Enterprises. In
this role, Ms. Bush acted as a global spokesperson for their
multi-national, direct-sales brand while leading their marketing,
operations, and research and development functions. As a member of their
executive committee, Ms. Bush was instrumental in developing Nu Skin
Enterprises' growth strategy while strengthening core competencies in the
areas of marketing and product development. She continues to chair Nu
Skin's Professional Advisory Board. From 1993 to 2000, Ms. Bush held
several leadership positions within the skin care franchise of the Johnson
& Johnson Consumer Products Companies. As Worldwide Executive Director,
Skin Care Ventures, Ms. Bush launched an incubator initiative in support of
Johnson & Johnson's portfolio of skin care brands. The mandate of this
initiative was the identification, assessment and development of new
product and business opportunities. She also held the position of Vice
President, Professional Marketing for Neutrogena for the first five years
of her tenure with Johnson & Johnson.
"The commercialization of our skin care peptides is the single highest
priority facing Helix BioMedix at present," according to R. Stephen Beatty,
President and Chief Executive Officer. "As a company, we welcome the
seasoned leadership that Lori will bring to our efforts in that area, and
we expect that her industry relationships and prior successes in the skin
care marketplace will help us aggressively accelerate our product and
partnership initiatives. We are delighted that Lori has decided to join the
company."
"During the past two decades, I have witnessed remarkable evolution in
the skin care industry as skin care professionals and consumers have both
come to embrace the possibilities associated with advanced ingredients in
topically- applied products. The demand for further advancements in this
area is not in any way slowing down," commented Bush. "The more we
understand the science of skin, the more important peptides will become in
our arsenal of therapies to keep skin looking youthful and healthy. That is
why I believe Helix BioMedix is ideally positioned to pave the way for next
generation advancement with their technology know-how and their library of
peptides. There is enormous promise in the area of peptide technology, and,
as of today, the skin care industry has a relatively undeveloped
perspective on this emerging area of skin science. The research efforts of
Helix BioMedix have greatly expanded the understanding, appreciation and
application of peptides in skin care. Helix BioMedix has identified
peptides with the potential to address acne, aging, inflammation, and a
number of other important skin care indications. I am looking forward to
being part of this dynamic company in fulfilling their mission to bring
science-driven skin care innovation to the marketplace."
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 1 million unique peptide sequences. The company's mission is
to become the industry leader in developing and commercializing small
proteins known as bioactive peptides. The antimicrobial and wound healing
properties of these peptides qualify them for inclusion in a wide range of
both pharmaceutical and consumer products. The company is currently focused
on the development of selected peptides as topical anti-infectives and in
wound healing. Non- pharmaceutical applications being pursued by Helix
BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care,
plant health, animal health and wide-spectrum biocides. More information
about the company and its proprietary peptides can be found on the
company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Investor Relations Contact:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
Company Contact:
David Kirske, CFO
425-402-8400
dkirske@helixbiomedix.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
Alison Ziegler, Investor Relations of Cameron
Associates, +1-212-554-5469, or alison@cameronassoc.com for Helix
BioMedix, Inc.; or David Kirske, CFO of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com
|
